Hosting a KOL event with a notable figure like Stephen Harrison, MD, to discuss the Phase 2a HERALD study of ALG-055009 in MASH positions Aligos Therapeutics in a positive light. This event could increase investor confidence by showcasing the drug's potential and the company's commitment to addressing unmet medical needs in liver diseases. The focus on the safety and efficacy of ALG-055009, a next-generation thyroid hormone beta agonist, could also attract attention from investors interested in novel therapeutics.